The U.S. Preventive Services Task Force (USPSTF) commissioned this review to inform the upcoming update of
its recommendation on postmenopausal hormone therapy for the primary prevention of chronic conditions. Among 9
trials that met inclusion criteria, estrogen plus progestin and estrogen alone decreased risk for fractures
but increased risk for stroke, thromboembolic events, gallbladder disease, and urinary incontinence. Estrogen
plus progestin increased risk for breast cancer and probable dementia, whereas estrogen alone decreased risk
for breast cancer.
Topics:
progestins, hormone replacement therapy, menopause, ischemic stroke, estrogen, fracture, advisory committees, follow-up, ...
Ann Intern Med. 2012;157(2):104-113. doi:10.7326/0003-4819-157-2-201207170-00466